LX 7101

Drug Profile

LX 7101

Alternative Names: LX-7101

Latest Information Update: 08 Apr 2016

Price : $50

At a glance

  • Originator Lexicon Pharmaceuticals
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action LIM kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Glaucoma; Ocular hypertension

Most Recent Events

  • 16 Mar 2016 No development reported - Phase-I/II for Ocular hypertension in USA (Topical)
  • 16 Mar 2016 No development reported - Phase-I/II for Glaucoma in USA (Topical)
  • 16 Aug 2012 Efficacy and adverse events data from a phase I/IIa trial in Glaucoma or Ocular hypertension released by Lexicon Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top